Nektar's Novel Opioid Unanimously Rejected by US FDA Advisory Cmte.
Executive Summary
But more data on abuse potential and efficacy could offer path for forward for oxycodegol even after the FDA product-specific advisory committee meeting for an opioid analgesic in more than a year goes very badly for the sponsor.
You may also be interested in...
Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues
The latest drug development news and highlights from our US FDA Performance Tracker.
J.P. Morgan Stockwatch: No Substitute For M&A
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.